Table 1 General characteristics of 147 patients with neuroblastoma
From: Prognostic factors for intermediate- or high-risk neuroblastomas in children in China
Characteristics | n | Survival status | ||
|---|---|---|---|---|
Deaths | Survival | P | ||
n = 67 | n = 80 | |||
Gender | 0.401 | |||
Boy | 97 (66.0) | 43 (44.3) | 54 (55.7) | |
Girl | 50 (34.0) | 24 (48.0) | 26 (52.0) | |
Age at diagnosis | 0.021 | |||
≤ 18 months | 36 (24.5) | 10 (27.8) | 26 (72.2) | |
18 months – 4 years | 57 (38.8) | 28 (49.1) | 29 (50.9) | |
> 4 years | 54 (36.7) | 29 (53.7) | 25 (46.3) | |
Economics regions | 0.05 | |||
Development | 41 (27.9) | 20 (40.8) | 29 (59.2) | |
Underdevelopment | 54 (36.7) | 20 (48.8) | 21 (51.2) | |
Backward | 52 (35.4) | 18 (34.6) | 34 (65.4) | |
Diagnosis date | 0.001 | |||
2006–2010 | 66 (44.9) | 43 (65.2) | 23 (34.9) | |
2011–2015 | 81 (55.1) | 24 (29.6) | 57 (70.4) | |
Primary site | 0.139 | |||
Retroperitoneal- adrenal-gland | 112 (76.2) | 47 (42.0) | 65 (58.0) | |
Mediastinal area | 23 (15.6) | 12 (52.2) | 11 (47.8) | |
Other sites* | 12 (8.2) | 8 (66.7) | 4 (33.3) | |
Metastasis sites | ||||
Bone marrow | 75 (50.3) | 36 (48.0) | 39 (52.0) | 0.332 |
Lung | 10 (6.8) | 8 (80.0) | 2 (20.0) | 0.026 |
Multi-bone | 96 (65.3) | 55 (57.3) | 41 (42.7) | 0.001 |
Intracranial metastasis | 22 (14.9) | 19 (86.4) | 3 (13.6) | 0.001 |
Liver | 29 (19.7) | 15 (51.7) | 14 (48.3) | 0.296 |
Distant lymph node | 62 (42.2) | 30 (48.4) | 32 (51.6) | 0.338 |
Spinal canal | 7 (4.8) | 3 (42.9) | 4 (57.1) | 0.498 |
Relapse | < 0.001 | |||
No | 74 (50.3) | 17 (23.0) | 57 (77.0) | |
Yes | 73 (49.7) | 50 (68.5) | 23 (31.5) | |
Risk-group | < 0.001 | |||
Intermediate-risk | 30 (20.4) | 3 (10.0) | 27 (90.0) | |
High-risk | 117 (79.6) | 64 (54.7) | 53 (45.3) | |
Received systematic chemotherapy | -- | |||
Yes | 147 (100) | 67 (45.6) | 80 (54.2) | |
No | 0 (0) | 0.00 | 0.00 | |
Received radiotherapy | 0.077 | |||
Yes | 17 (11.6) | 11 (64.7) | 6 (35.3) | |
No | 130 (88.4) | 56 (43.1) | 74 (56.9) | |
Received APBSCT | 0.001 | |||
Yes | 35 (76.2) | 25 (71.4) | 10 (28.6) | |
No | 112 (23.8) | 42 (37.5) | 70 (62.5) | |
Efficacy of induction chemotherapy# | 0.001 | |||
CR | 96 (66.2) | 31 (32.3) | 65 (67.7) | |
PR | 32 (22.1) | 18 (56.3) | 14 (43.8) | |
PD | 17 (11.7) | 16 (94.1) | 1 (5.9) | |
NMYC status | 0.262 | |||
Yes | 50 (34.0) | 26 (52.0) | 24 (48.0) | |
No | 97 (66.0) | 41 (42.3) | 56 (57.7) | |
Year for admission | < 0.001 | |||
2006–2010 | 66 (44.9) | 43 (65.2) | 23 (34.8) | |
2011–2015 | 81 (55.1) | 24 (29.6) | 57 (70.4) | |